Interests: Breast cancer, Breast reconstruction, Regenerative medicin, Mesenchymal stem cells, Breast, Cosmetic surgery, Breast augmentation
Special Issue Information
Breast cancer is the most common cancer and the second cause of cancer deaths worldwide. Consequentely there is an urgent need to develop new therapeutic agents and treatment strategies that are effective against this cancer. Treatment options for patients suffering from breast cancerare classicicaly based on cytotoxic chemotherapy or antiestrogen treatment. New treatment startegies are directed towards newly identified targets. Thus breast cancer treatment is getting more and more tumor type specific resulting in an improved outcome combined with new side effects.
In this special issue the authors will present the most innovative treatment strategies for breast cancer based on the molecular patholological character of the tumor like luminal A/B, triple negative and Her2 overexpressing breast cancer. Thus, innovative endocrine treatment options for example CDK 4/6 inhibitors and PI3K-inhibitors will be discussed for endocrine responsibel berast cancer. In triple negative breast cancer the importance of neoadjuvant treatment is presented combined with the newly accepted inhibition of the PDL1 pathway. In addition the meaningful results of PARP inhibition in BRCA mutated breast cancer are analyzed. For Her2 overexpressing breast cancer all treatment options of inhibiting this pathway with regard to the actual studies are presented for the neoadjuvant, adjuvant, post neoadjuvant and metastatic setting are presented. Last but not least the actual recommendations for oncologic and oncoplastic surgery including sentinel lymph node resection are discussed.
This issue should give a summary of the modern treatment strategies in breast cancer with a special aspect on the actual guidelines and recommendation of the new systemic treatment options.
Prof. Dr. Michael Friedrich
Manuscript Submission Information
Manuscripts should be submitted online at https://ejgo.imrpress.combyregisteringandlogging into this website. Once you are registered,click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on theInstructions for Authorspage. European Journal of Gynaecological Oncology is an international peer-reviewed open access quarterly journal published by IMR Press.
Please visit theInstructions for Authorspage before submitting a manuscript. TheArticle Processing Charge (APC)for publication in thisopen accessjournal is $1250. We normally offer a discount greater than 30% (APC: $850) to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.
Breast cancer, Systemic treatment, Adjuvant setting, Metastatic setting, Genetic councelling, Triple negative breast cancer, Her2+ breast cancer, Endocrine treatment